The Company is a Korea-based company primarily engaged in the manufacture and sale of biopharmaceuticals. The Company is engaged in the manufacture and sale of vaccine, peptide nucleic acid complex. The Company is also engaged in the provision of Cell Penetrating Peptide (CPP) platform services. In addition, the Company is engaged in the development and research of vaccines, such as tuberculosis vaccines for adults and adolescents, and COVID-19 vaccines. The Company was established on July 15, 2016. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on June 15, 2023.
Headquarters
306-ho, 13, Teheran-ro 64-gil Gangnam-gu Seoul
Seoul; Seoul;
Contact Details: Purchase the Quratis Inc. (Seoul) report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service